Two photoactive Ru (II) compounds based on tetrazole ligands for photodynamic therapy

Yang, Jie; He, Xin; Ke, Zhen; Chen, Jianjiao; Zou, Zhenyuan; Wei, Bo; Zou, Dengfeng; Zou, Jianhua

doi:10.1016/j.jinorgbio.2020.111127

Cited by 15 publications

(9 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In previous studies, we have reported a series of tetrazole carboxylate–based complexes as nanoboosters, which can boost O 2 or H 2 O 2 to generate ROS to induce cancer cell apoptosis, exhibiting high toxicity and excellent biocompatibility for photodynamic therapy ( Yang G et al, 2018 ; Zhai et al, 2018 ; Yang et al, 2019 ; Zhu et al, 2019 ; Xu et al, 2020 ; Yang et al, 2020 ). As an extension of our research, the tetrazole carboxylic acid ligand–based H 4 L ( Scheme 1 ) was selected for self-assembly with Gd(III)–Cu(II) ions, and a new heteronuclear complex [Gd 2 Cu(L) 2 (H 2 O) 10 ]·6H 2 O was obtained with good antitumor properties ( Scheme 1 ).…”

Section: Introductionmentioning

confidence: 99%

Rational Design of a Gd(III)–Cu(II) Nanobooster for Chemodynamic Therapy Against Cancer Cells

et al. 2022

View full text Add to dashboard Cite

Copper (II) containing coordination complexes have attracted much attention for chemodynamic therapy (CDT) against cancer cells. In this study, the bimetallic nanobooster [Gd2Cu(L)2(H2O)10]·6H2O was prepared by a solvothermal method based on tetrazole carboxylic acid ligand H4L [H4L = 3,3-di (1H-tetrazol-5-yl) pentanedioic acid]. It showed considerable cytotoxicity toward three kinds of human cancer cells (HeLa, HepG2, and HT29). The MTT assay showed that the IC50 (half-maximal inhibitory concentration) of the complex NPs on HeLa cells (4.9 μg/ml) is superior to that of HepG2 (11.1 μg/ml) and HT29 (5.5 μg/ml). This result showed that [Gd2Cu(L)2(H2O)10]·6H2O NPs can inhibit cell proliferation in vitro and may be potential candidates for chemodynamic therapy. In addition, the cytotoxicity was also confirmed by the trypan blue staining experiment. The results promise the great potential of Gd(III)–Cu(II) for CDT against cancer cells.

show abstract

Section: Introductionmentioning

confidence: 99%

Rational Design of a Gd(III)–Cu(II) Nanobooster for Chemodynamic Therapy Against Cancer Cells

et al. 2022

View full text Add to dashboard Cite

show abstract

“…In a previous study, a series of tetrazole-carboxylate-based mononuclear ruthenium(II) complexes were synthesized, which exhibited low dark toxicity, high excited-state reactivity and excellent biocompatibility when used in photodynamic therapy, and Cu(II), Sm(III), Ca(II) complexes based on these ligands also have low IC 50 values against cancer cells. [20][21][22][23][24][25] In this study, we focus on Co(II) complexes based on H 3 tzpha, Hpztzma and Hpytza (Scheme 1). As a result, three complexes [Co 3 (tzpha) 2 (4,4'bipy) 3…”

Section: Introductionmentioning

confidence: 99%

“…As a multifunctional material, coordination complexes have been widely prepared and actively used in the treatment of cancer, and the complexes based on tetrazole‐carboxylate have shown a good inhibitory effect on tumor cell proliferation in the application of anticancer. In a previous study, a series of tetrazole‐carboxylate‐based mononuclear ruthenium(II) complexes were synthesized, which exhibited low dark toxicity, high excited‐state reactivity and excellent biocompatibility when used in photodynamic therapy, and Cu(II), Sm(III), Ca(II) complexes based on these ligands also have low IC 50 values against cancer cells [20–25] . In this study, we focus on Co(II) complexes based on H 3 tzpha, Hpztzma and Hpytza (Scheme 1).…”

Section: Introductionmentioning

confidence: 99%

Synthesis, Characterization and Bioactivity of Three Tetrazole Carboxylate Based Co(II) Complexes

et al. 2022

Self Cite

View full text Add to dashboard Cite

As a kind of multifunctional materials with high porosity, tunable pore structure and easy functionalization, coordination complexes have been widely used in various fields. Here, three complexes were prepared by self‐assembly with Co(II) ions using tetrazolylacetic acids as ligands, 2,2′,2′′‐(benzene‐1,3,5‐triyltris(2H‐tetrazole‐5,2‐diyl)) triacetic acid (H3tzpha), 2‐(5‐(pyrazin‐2‐yl)‐2H‐tetrazol‐2‐yl) propanoic acid (Hpztzma) and 2‐(5‐(pyridin‐2‐yl)‐2H‐tetrazol‐2‐yl) acetic acid (Hpytza), and were characterized by X‐ray crystallography. These complexes can also self‐assemble into nanoparticles (NPs) in aqueous solution by nanocoprecipitation. In vitro CCK‐8 assay on three kind of human cancer cells (HeLa, HepG2 and Huh7) cells showed these Co(II) complexes have the best cytotoxicity against HeLa cells. And complex 1 had a half maximal inhibitory concentration (IC50 value) of 14.8 μg mL−1, which was superior to 16.5 μg mL−1 and 15.2 μg mL−1 of complex 2 and 3. In addition, the effect of different ligands on cancer cell ablation was explored. The results showed the three NPs can effectively inhibit the proliferation of cancer cells in vitro and provided a strategy on designing highly efficient anticancer materials based on coordination complexes.

show abstract

“…When terazol ligands were coordinated to ruthenium(II) the resulting complex (Figure 8: RU13) was capable of forming nanoparticles that showed exceptional cellular accumulation but negligible cytotoxicity in the dark even at high concentrations. These complexes inhibited tumor growth and migration after excitation at 490 nm, which is just outside the ideal optic window for tissue [65].…”

Section: Othermentioning

confidence: 99%

“…Figure 8. Other examples of ruthenium complexes: RU10, where NˆN = DPPZ[62]; RU11, where NˆN = BPY[63]; RU12, where NˆN = PHEN[64]; RU13, where NˆN = BPY[65]; RU14, where NˆN = PHEN[66]; RU15, where NˆN = POP[67]; and Eu-linked ruthenium complex RU16, where NˆN = BPY[68].…”

mentioning

confidence: 99%

Photoactive and Luminescent Transition Metal Complexes as Anticancer Agents: A Guiding Light in the Search for New and Improved Cancer Treatments

McGhie

Aldrich‐Wright

2022

Biomedicines

View full text Add to dashboard Cite

Cancer continues to be responsible for the deaths of more than 9 million people worldwide each year. Current treatment options are diverse, but low success rates, particularly for those with late-stage cancers, continue to be a problem for clinicians and their patients. The effort by researchers globally to find alternative treatment options is ongoing. In the present study, we focused on innovations in inorganic anticancer therapies, specifically those with photoactive and luminescent properties. Transition metals offer distinct advantages compared to wholly organic compounds in both chemotherapeutics and luminescence properties. Here we report on the characteristics that result from discrete structural changes that have been expertly used to fine-tune their properties, and how diverse inherent luminescent properties have been widely employed to monitor cellular localization to photodynamic therapy.

show abstract

Two photoactive Ru (II) compounds based on tetrazole ligands for photodynamic therapy

Cited by 15 publications

References 32 publications

Rational Design of a Gd(III)–Cu(II) Nanobooster for Chemodynamic Therapy Against Cancer Cells

Rational Design of a Gd(III)–Cu(II) Nanobooster for Chemodynamic Therapy Against Cancer Cells

Synthesis, Characterization and Bioactivity of Three Tetrazole Carboxylate Based Co(II) Complexes

Photoactive and Luminescent Transition Metal Complexes as Anticancer Agents: A Guiding Light in the Search for New and Improved Cancer Treatments

Contact Info

Product

Resources

About